GeoVax Labs (GOVX) and The Competition Critical Comparison

GeoVax Labs (NASDAQ:GOVX) is one of 844 public companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare GeoVax Labs to similar companies based on the strength of its valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends and risk.

Volatility & Risk

GeoVax Labs has a beta of 3.85, suggesting that its stock price is 285% more volatile than the S&P 500. Comparatively, GeoVax Labs’ peers have a beta of -1.84, suggesting that their average stock price is 284% less volatile than the S&P 500.

Earnings & Valuation

This table compares GeoVax Labs and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
GeoVax Labs	$2.49 million	-$21.47 million	-0.18
GeoVax Labs Competitors	$756.09 million	$13.58 million	-19.00

GeoVax Labs’ peers have higher revenue and earnings than GeoVax Labs. GeoVax Labs is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares GeoVax Labs and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-743.64%	-394.74%
GeoVax Labs Competitors	-12,323.33%	-195.38%	-30.39%

Insider & Institutional Ownership

6.1% of GeoVax Labs shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 0.2% of GeoVax Labs shares are owned by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and recommmendations for GeoVax Labs and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1	1	1	0	2.00
GeoVax Labs Competitors	9869	15283	45612	1598	2.54

GeoVax Labs presently has a consensus target price of $3,600.00, indicating a potential upside of 179,451.12%. As a group, “Biotechnology” companies have a potential upside of 99.39%. Given GeoVax Labs’ higher probable upside, equities analysts plainly believe GeoVax Labs is more favorable than its peers.

Summary

GeoVax Labs peers beat GeoVax Labs on 9 of the 13 factors compared.

GeoVax Labs Company Profile

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer. The company’s technology platform is based primarily on modified vaccinia Ankara (MVA) and virus-like particle (VLP) vaccine technologies, which are designed to generate broad and durable immune responses. GeoVax’s pipeline has included GEO-CM04S1, a multivalent COVID-19 vaccine candidate intended to address emerging coronavirus variants, as well as investigational vaccines for HIV, hemorrhagic fever viruses such as Ebola and Marburg, and other infectious diseases.